Member access

4-Traders Homepage  >  Shares  >  Euronext Paris  >  BioAlliance Pharma SA    C4X   

 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Company
Onxeo SA engages in the development of drugs for the treatment of cancer.The firm produces and develops ophan oncology products under the brand names Livatag, Validive, Beleodaq, and AMEP.It also offers specialty products under the brand names Loramyc/Oravig, Sitavig, and Fluriad.The company was... 
Sector
Pharmaceuticals
Calendar
10/23Earnings Release
Surperformance© rating of BioAlliance Pharma SA
Trading Rating : - Investor Rating :
More about the company
Financials (€)
Sales 2014 17,1 M
EBIT 2014 -1,82 M
Net income 2014 -1,66 M
Finance 2014 37,0 M
Yield 2014 -
Sales 2015 5,02 M
EBIT 2015 -15,0 M
Net income 2015 -15,6 M
Debt 2015 -
Yield 2015 -
PER 2014 -
PER 2015
Capi. / Sales 2014 11,7x
Capi. / Sales 2015 47,2x
Capitalization 237 M
More Financials
Latest news on BIOALLIANCE PHARMA SA
3d ago ONXEO : Participates in InvestorDagen 2014
6d ago ONXEO : receives “Silver Governance” – Corporate Governance-pr..
7d ago ONXEO : announces participation in the Midcap Event On October 2nd and 3rd, 2014..
7d ago ONXEO : announces participation in the Midcap Event On October 2nd and 3rd, 2014..
09/24 ONXEO : Participates in InvestorDagen 2014
09/24 ONXEO : Participates at InvestorDagen 2014
09/19 ONXEO : attends InvestorDagen 2014, the largest Danish private investor event / ..
09/10 ONXEO : Gets U.S. Patent for Beleodaq
09/03 ONXEO : Receives U.S. Patent for Beleodaq
08/28 ONXEO : strengthens Beleodaq® patent protection in the U.S. until 2027 – O..
08/28 ONXEO : Key milestones and consolidated accounts – First six months 2014 /..
08/06 BIOALLIANCE PHARMA : Data on Dermatology Drugs Detailed by Researchers at BioAll..
More news
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF